Search

The International Federation of Gynecology and Obstetrics (FIGO) has recognized serous tubal intraepithelial carcinoma as a precursor lesion for high‐grade serous epithelial ovarian cancer. Future staging systems should consider reclassifying stage based on tumor biologic behavior. [ABSTRACT FROM AUTHOR]

Ovarian, fallopian tube, and peritoneal cancers have a similar clinical presentation and are treated similarly, and current evidence supports staging all 3 cancers in a single system. The primary site (i.e. ovary, fallopian tube, or peritoneum) should be designated where possible. The histologic type should be recorded. Intraoperative rupture ("surgical spill") is IC1; capsule ruptured before surgery or tumor on ovarian or fallopian tube surface is IC2; and positive peritoneal cytology with or without rupture is IC3. The new staging includes a revision of stage III patients; assignment to stage IIIA1 is based on spread to the retroperitoneal lymph nodes without intraperitoneal dissemination. Extension of tumor from omentum to spleen or liver (stage IIIC) should be differentiated from isolated parenchymal metastases (stage IVB). [ABSTRACT FROM AUTHOR]

A response from the author of the article "Staging classification for cancer of the ovary and fallopian tube should include in situ carcinoma" in the previous issue is presented.

A letter to the editor is presented in response to the article "Staging classification for cancer of the ovary and fallopian tube should include in situ carcinoma" in the previous issue.